| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/EURHEARTJ/EHT528 |
| P8608 | Fatcat ID | release_qkbj2rajffhodlhpam5rbfzc4q |
| P698 | PubMed publication ID | 24408888 |
| P50 | author | Lars G Hemkens | Q56917103 |
| P2093 | author name string | Heiner C Bucher | |
| P2860 | cites work | Prediction of Coronary Heart Disease Using Risk Factor Categories | Q22241923 |
| The Biology of Atherosclerosis: General Paradigms and Distinct Pathogenic Mechanisms Among HIV-Infected Patients | Q26862601 | ||
| Inflammatory and coagulation biomarkers and mortality in patients with HIV infection | Q28473903 | ||
| Inflammation, coagulation and cardiovascular disease in HIV-infected individuals | Q28483645 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy | Q29616232 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study | Q30573969 | ||
| Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study | Q31146395 | ||
| Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? | Q33184007 | ||
| Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study | Q33521080 | ||
| Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. | Q33576435 | ||
| Hypertension and HIV Infection | Q38071742 | ||
| HIV and coronary heart disease: time for a better understanding | Q38078094 | ||
| Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects | Q39035145 | ||
| Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). | Q42280176 | ||
| The mechanism of insulin resistance caused by HIV protease inhibitor therapy. | Q42802122 | ||
| Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st | Q43208808 | ||
| Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy | Q43707009 | ||
| Impact of HIV infection and HAART on serum lipids in men. | Q44473694 | ||
| Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study | Q44486385 | ||
| A critical epidemiological review of cardiovascular disease risk in HIV-infected adults: the importance of the HIV-uninfected comparison group, confounding, and competing risks. | Q44532412 | ||
| Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy | Q44609997 | ||
| Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial | Q45369180 | ||
| Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. | Q45733605 | ||
| Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study | Q46546975 | ||
| Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia | Q46549304 | ||
| HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial | Q47853584 | ||
| All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration | Q47918470 | ||
| n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia | Q51355736 | ||
| Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment | Q51388029 | ||
| Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study | Q56530639 | ||
| Elevated triglycerides and risk of myocardial infarction in HIV-positive persons | Q57180899 | ||
| Small Dense Lipoproteins, Apolipoprotein B, and Risk of Coronary Events in HIV-Infected Patients on Antiretroviral Therapy | Q57709917 | ||
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study | Q33602915 | ||
| Lipoprotein particle subclasses, cardiovascular disease and HIV infection. | Q33639078 | ||
| Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection | Q33857515 | ||
| Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data | Q33946279 | ||
| Association Between Systemic Inflammation and Incident Diabetes in HIV-Infected Patients After Initiation of Antiretroviral Therapy | Q34153519 | ||
| No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis | Q34296639 | ||
| Effect of different antilipidemic agents and diets on mortality: a systematic review | Q34410711 | ||
| Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study | Q34415980 | ||
| HIV protease inhibitors acutely impair glucose-stimulated insulin release. | Q34455624 | ||
| Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review | Q34651525 | ||
| n-3 fatty acids in patients with multiple cardiovascular risk factors | Q34651597 | ||
| Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). | Q34762935 | ||
| Plasma levels of soluble CD14 independently predict mortality in HIV infection | Q34764002 | ||
| Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial | Q35101789 | ||
| The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. | Q35166131 | ||
| Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study | Q35189974 | ||
| Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study | Q35644326 | ||
| Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy | Q35844759 | ||
| Risk Factors for ESRD in HIV-Infected Individuals: Traditional and HIV-Related Factors | Q35883947 | ||
| Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population | Q35949949 | ||
| Body Composition and Metabolic Changes in HIV-Infected Patients | Q35949965 | ||
| Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. | Q36198650 | ||
| HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation | Q36383621 | ||
| Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir | Q36578046 | ||
| Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya | Q36723349 | ||
| Carotid Intima-Media Thickness Among Human Immunodeficiency Virus–Infected Patients Without Coronary Calcium | Q36808270 | ||
| Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial | Q36868568 | ||
| Arterial inflammation in patients with HIV. | Q37046942 | ||
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration | Q37208045 | ||
| Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease | Q37390635 | ||
| Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. | Q37458941 | ||
| Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). | Q37561659 | ||
| Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection | Q37600614 | ||
| Lipodystrophy: metabolic insights from a rare disorder | Q37792647 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| P304 | page(s) | 1373-1381 | |
| P577 | publication date | 2014-01-09 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | HIV infection and cardiovascular disease | |
| P478 | volume | 35 |
| Q58699124 | A Low Frequency of IL-17-Producing CD8 T-Cells Is Associated With Persistent Immune Activation in People Living With HIV Despite HAART-Induced Viral Suppression |
| Q89081067 | A cross-sectional analysis of cardiovascular disease in the hemophilia population |
| Q55001110 | Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials. |
| Q47204696 | Adipokines levels in HIV infected patients: lipocalin-2 and fatty acid binding protein-4 as possible markers of HIV and antiretroviral therapy-related adipose tissue inflammation. |
| Q30249830 | Advances in biosensing strategies for HIV-1 detection, diagnosis, and therapeutic monitoring |
| Q92485293 | Adverse reactions to antiretroviral therapy: a prevalent concern |
| Q35925152 | Ambulatory Blood Pressure Monitoring in Individuals with HIV: A Systematic Review and Meta-Analysis |
| Q36168754 | Anti-α4 Integrin Antibody Blocks Monocyte/Macrophage Traffic to the Heart and Decreases Cardiac Pathology in a SIV Infection Model of AIDS. |
| Q37643812 | Association of Arterial and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Infection |
| Q89126294 | Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management |
| Q59138073 | Benchmarks of Diabetes Care in Men Living With Treated HIV-Infection: A Tertiary Center Experience |
| Q51251254 | Body fat redistribution and changes in lipid and glucose metabolism in people living with HIV/AIDS. |
| Q89674875 | Cardiovascular Conditions of Patients on HIV Therapy |
| Q51779710 | Cardiovascular Disease in the Setting of Human Immunodeficiency Virus Infection |
| Q92696173 | Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study |
| Q50047696 | Cataract Surgery in HIV Seropositive Patients: Long-Term Follow-Up. |
| Q40080114 | Cholesterol Screening and Statin Prescription is Low Among HIV-Infected Patients on Protease-Inhibitor Regimens in Botswana |
| Q64977254 | Clinical Use of Cardiac Magnetic Resonance in Systemic Heart Disease. |
| Q90612746 | Comorbidity of HIV, hypertension, and diabetes and associated factors among people receiving antiretroviral therapy in Bahir Dar city, Ethiopia |
| Q38591208 | Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis. |
| Q35190397 | Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy |
| Q64272846 | Contribution of Human Herpesvirus 8 and Herpes Simplex Type 2 to Progression of Carotid Intima-Media Thickness in People Living With HIV |
| Q28075282 | Cross-sectional imaging of aortic infections |
| Q89464543 | Cumulative HIV viremia copy-years and hypertension in people living with HIV |
| Q40278259 | Dietary Inadequacies in HIV-infected and Uninfected School-aged Children in Johannesburg, South Africa. |
| Q46451498 | Disparities in Management of Cardiovascular Disease in Rural South Africa: Data From the HAALSI Study (Health and Aging in Africa: Longitudinal Studies of International Network for the Demographic Evaluation of Populations and Their Health Communiti |
| Q54204331 | Dyslipidemia among rural and urban HIV patients in south-east Malawi |
| Q89674865 | Estimating Cardiovascular Risk in HIV-Infected Patients |
| Q92277511 | Excess Risk for Atherosclerotic Cardiovascular Outcomes Among US Adults With HIV in the Current Era |
| Q28079826 | Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV |
| Q41271570 | HIV patients have impaired diastolic function that is not aggravated by anti-retroviral treatment. |
| Q45827500 | HIV protease inhibitor-induced cardiac dysfunction and fibrosis is mediated by platelet-derived TGF-β1 and can be suppressed by exogenous carbon monoxide |
| Q41995759 | Healthcare utilization and direct costs of non-infectious comorbidities in HIV-infected patients in the USA. |
| Q40656708 | Heart failure in patients with human immunodeficiency virus infection: Epidemiology and management disparities |
| Q46160196 | High rates of hypertension, diabetes, elevated low-density lipoprotein cholesterol, and cardiovascular disease risk factors in HIV-infected patients in Malawi |
| Q50103684 | Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update. |
| Q40228558 | Hypertension management in a population of older adults in rural South Africa |
| Q38830540 | Immune activation and neuroinflammation in alcohol use and HIV infection: evidence for shared mechanisms |
| Q41738666 | Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults. |
| Q26851535 | Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus |
| Q35005863 | JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals |
| Q35864381 | Lung and Heart Diseases Are Better Predicted by Pack-Years than by Smoking Status or Duration of Smoking Cessation in HIV Patients |
| Q38597452 | Mechanisms Influencing Circadian Blood Pressure Patterns Among Individuals with HIV. |
| Q37673041 | Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors. |
| Q36136807 | Missed Opportunities to Address Cardiovascular Disease Risk Factors amongst Adults Attending an Urban HIV Clinic in South Africa |
| Q35021031 | Mobile phone text messaging interventions for HIV and other chronic diseases: an overview of systematic reviews and framework for evidence transfer |
| Q39622641 | Non-linear resistance training reduces inflammatory biomarkers in persons living with HIV: A randomized controlled trial |
| Q46130631 | Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells |
| Q33853259 | Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls |
| Q38721214 | Race and sex differences in ambulatory blood pressure measures among HIV+ adults |
| Q52626860 | Regulatory CD4+ T Cells Recognize MHC-II-Restricted Peptide Epitopes of Apolipoprotein B. |
| Q35861534 | Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons. |
| Q37320521 | Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study. |
| Q35089263 | Stimulating high impact HIV-related cardiovascular research: recommendations from a multidisciplinary NHLBI Working Group on HIV-related heart, lung, and blood disease |
| Q38813848 | Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens |
| Q34477247 | Tackling cardiovascular co-morbidities in HIV-positive patients: who, how and where? |
| Q40678434 | The Framingham function overestimates the risk of ischemic heart disease in HIV-infected patients from Barcelona. |
| Q33893572 | The association between HIV (treatment), pregnancy serum lipid concentrations and pregnancy outcomes: a systematic review |
| Q58590756 | The global burden of multiple chronic conditions: A narrative review |
| Q43505499 | The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure. |
| Q54217910 | The role of HIV Tat protein in HIV-related cardiovascular diseases |
| Q38764695 | The role of tenofovir alafenamide in future HIV management |
| Q37414416 | Therapeutic Drug Monitoring of Anti-human Immunodeficiency Virus Drugs in a Patient with Short Bowel Syndrome |
| Q34156186 | Tobacco smoking in HIV-infected versus general population in france: heterogeneity across the various groups of people living with HIV. |
Search more.